Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793245 | 0.90 | POLB (0.88) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL5307467 | 0.85 | POLB (0.73) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL12793258 | 0.85 | POLB (1.00) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL3252762 | 0.84 | KMT2A (0.73) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL5915275 | 0.84 | POLB (0.71) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL28072234 | 0.83 | POLB (0.76) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL8871272 | 0.83 | POLB (0.76) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL12793270 | 0.83 | POLB (0.96) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL12793250 | 0.83 | POLB (0.96) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL23536066 | 0.82 | USP2 (0.69) | POLBLMNASMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| CN-105143206-B | Pyrimidine -2,4- diamine derivative for treating cancer | 托马斯·黑勒戴药物研究基金会 | 2019-01-15 | — | — | CN | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| CN-106008322-B | sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2018-09-04 | — | — | CN | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| EP-1963255-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007071452-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007067994-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | POLB 325/4885LMNA 4724/4885SMN1; SMN2 562/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | POLB 3778/4885LMNA 3607/4885SMN1; SMN2 3353/4885 |
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | HDAC6, HDAC1, HDAC3 | POLB 577/4885LMNA 1338/4885SMN1; SMN2 232/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | POLB 325/4885LMNA 4724/4885SMN1; SMN2 562/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | POLB 1116/4885LMNA 4818/4885SMN1; SMN2 1315/4885 |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | POLB 4410/4885LMNA 849/4885SMN1; SMN2 2892/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | POLB 1116/4885LMNA 4818/4885SMN1; SMN2 1315/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | POLB 1116/4885LMNA 4818/4885SMN1; SMN2 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.